Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

p-Cresyl Sulfate.

Tessa Gryp1,2, Raymond Vanholder3, Mario Vaneechoutte4

  • 1Department of Internal Medicine, Nephrology Division, Ghent University Hospital, 9000 Ghent, Belgium. tessa.gryp@ugent.be.

Toxins
|February 2, 2017
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Kidney dysfunction regulates gut transporters.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
Same author

Supplementation with <i>Enterococcus lactis</i> (SF68) and its association with biochemical parameters and inflammatory biomarkers related to renal impairment in dogs with chronic kidney disease.

The veterinary quarterly·2026
Same author

Kidney Function Modulates Gut Microbial Metabolism.

Toxins·2026
Same author

Corrigendum to "Ceftriaxone administration reduces vascular calcification associated with experimental models of chronic kidney disease." [Biomed. Pharmacother. 197 (2026), 119131].

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
Same author

Ceftriaxone administration reduces vascular calcification associated with experimental models of chronic kidney disease.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
Same author

Chronic Kidney Disease-Associated Defect in Humoral Immune Response Is Driven by Inflammation.

Toxins·2026
Same journal

Chemical, Biological, and Ecological Evidence for Aerobic Deoxynivalenol Detoxification in Agronomic Soil-Derived Bacterial Communities.

Toxins·2026
Same journal

Botulinum Toxin Treatment for Uncommon Phenotypes of Laryngeal Adductor Breathing Dystonia.

Toxins·2026
Same journal

Enhancing Neuronal Networks with <i>Rhinella schneideri</i> Skin Secretion Molecules: Implications for Neurodegenerative Disorders.

Toxins·2026
Same journal

Dangerous Measures: A Case Report and Review of Motoro Ray Envenomation.

Toxins·2026
Same journal

The Impact of OnabotulinumtoxinA on Oral Pain Medication Prescription Fills and Low-Value Care in Patients with Cervical Dystonia in the United States: A Retrospective Claims Analysis.

Toxins·2026
Same journal

Broad-Spectrum Antiviral and Antibacterial Activity of the Scorpion Venom Peptide HP1090.

Toxins·2026
See all related articles

p-Cresyl sulfate (pCS) is a toxic uremic solute linked to poor outcomes in chronic kidney disease (CKD). Targeting gut bacteria may reduce pCS levels and slow CKD progression.

Area of Science:

  • Nephrology
  • Microbiology
  • Toxicology

Background:

  • Chronic kidney disease (CKD) is characterized by impaired kidney function and the retention of uremic solutes.
  • Uremic toxins, such as p-cresyl sulfate (pCS), contribute to the adverse effects observed in CKD patients.
  • Increased pCS levels correlate with poorer clinical outcomes in individuals with CKD.

Purpose of the Study:

  • To review the biological effects of p-cresyl sulfate (pCS).
  • To elucidate the metabolic origin of pCS within the intestinal environment.
  • To explore the potential of targeting gut microbiota for managing pCS levels in CKD.

Main Methods:

  • Literature review summarizing existing studies on pCS.
  • Analysis of in vitro data on bacterial families involved in phenolic compound production.
Keywords:
chronic kidney diseaseintestinal microbiotap-cresyl sulfate

Related Experiment Videos

  • Discussion of pCS removal challenges with dialysis.

    • Main Results:

    • pCS is a protein-bound uremic toxin with attributed biological and biochemical toxic effects.
    • pCS originates from the gut microbiota's metabolism of aromatic amino acids like tyrosine and phenylalanine.
    • Specific bacterial families, including Bacteroidaceae and Lactobacillaceae, are identified as producers of phenolic compounds like pCS.

    Conclusions:

    • pCS is a significant uremic toxin associated with negative CKD outcomes.
    • The gut microbiota plays a crucial role in pCS generation.
    • Modulating the gut microbiota presents a potential therapeutic strategy to reduce pCS toxicity and slow CKD progression, even in early stages, and mitigate cardiovascular risk.